TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28662049
Drug: SD+AMX+MET (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: SD+AMX+MET (both 500mg x 3 times daily TID) for 7 days (group C)
Study: 26199386
Drug: Cilengitide 2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilengitide 2,000 mg administered intravenously twice weekly (arm A)
Study: 26199386
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (arm B)
Study: 23922748
Drug: Partially hydrogenated
Normalized name: SOY OIL,PARTIALLY HYDROGENATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially hydrogenated soybean oil providing 15.7 g/day of TFA (trans18:1)
Study: 17429507
Drug: Homeopathic preparations
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic preparations and practice
Study: 8857120
Drug: Intratracheal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratracheal administration of preservative-free fentanyl
Study: 8857120
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of preservative-free fentanyl
Study: 1542851
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (LD) radiotherapy: five times 2 Gy daily fractions to a total dose of 10 Gy
Study: 1542851
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (HD) radiotherapy: ten times 2 Gy (8 patients) or five times 3.5 Gy (20 patients)
Study: 24819685
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment outcome
Study: 1542851
Drug: Treatment failures
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment failures related to Brooker score
Study: 27522159
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral immunotherapy (E-OIT) at goal maintenance doses of 300 mg/d
Study: 27522159
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral immunotherapy (E-OIT) at goal maintenance doses of 3000 mg/d
Study: 27522159
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral immunotherapy (E-OIT) overall
Study: 27522159
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral immunotherapy (E-OIT)
Study: 19547761
Drug: Postoperative gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative gabapentin (GBP) 100 mg three times per day (G3)
Study: 19547761
Drug: Postoperative gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative gabapentin (GBP) 200 mg three times per day (G4)
Study: 19547761
Drug: Postoperative gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative gabapentin (GBP) 300 mg three times per day (G5)
Study: 19547761
Drug: Preoperative gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative gabapentin 600 mg/postoperative placebo (G2)
Study: 17306709
Drug: Stentless biological
Normalized name: gentian, stemless, whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stentless biological valve
Study: 17306709
Drug: Stented biological
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stented biological valve
Study: 15076170
Drug: Lacidipine 4
Normalized name: lacidipine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine 4 mg/day
Study: 10489824
Drug: Leukotriene antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Leukotriene antagonist
Study: 1713987
Drug: Nicardipine (0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (0.06 mg/kg/min)
Study: 2580712
Drug: Lorcainide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcainide (2 mg/kg)
Study: 29481391
Drug: Intraoperative intercostal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative intercostal and pectoral nerve blocks with 0.25% bupivacaine with 1:200,000 epinephrine and 4 mg of dexamethasone
Study: 27855103
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA)‐selection of sperm (physiological intracytoplasmic sperm injection, PICSI)
Study: 23563024
Drug: n‐3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 PUFA 1 g daily
Study: 17491171
Drug: Internet-administered questionnaires
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-administered questionnaires
Study: 17491171
Drug: Telephone-administered questionnaires
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered questionnaires
Study: 14605015
Drug: Antithrombotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic therapy (enoxaparin or unfractionated heparin in combination with tirofiban or placebo) for 2 to 8 days in TETAMI randomized patients.
Study: 14605015
Drug: Reperfusion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reperfusion therapy (lytic or primary PCI) in registry patients who received reperfusion.
Study: 14605015
Drug: Registry patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Registry patients who did not receive reperfusion therapy.
Study: 11027741
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of melatonin
Study: 11027741
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of melatonin followed by 0.5 mg per day
Study: 15724865
Drug: Magnesium therapy
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium therapy
Study: 1410588
Drug: Nicotinamide (1-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide (1-6 g oral doses)
Study: 19826403
Drug: Rexin-G (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rexin-G (dose 0-1)
Study: 19826403
Drug: Rexin-G (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rexin-G (dose 2)
Study: 16614849
Drug: Gemcitabine (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1,200 mg/m²) as a 2-h continuous infusion (10 mg/m² per min) on days 1 and 8 of each cycle plus AUC 5 carboplatin on day 1, repeated every 21 days.
Study: 29319497
Drug: Tigecycline monotherapy
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tigecycline monotherapy
Study: 9471048
Drug: Intracavernous injection
Normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernous injection (ICI) of etilefrin
Study: 2676659
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g fish oil concentrate (30% omega 3FAs) daily
Study: 2676659
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g safflower oil daily
Study: 201203
Drug: Sex hormone
Normalized name: Sex hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex hormone treatment
Study: 201203
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (CaCO3) treatment
Study: 31429198
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (as-treated)
Study: 28994678
Drug: Insulin (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (continuous infusion)
Study: 28994678
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg tablets twice daily)
Study: 9371205
Drug: Parental smoking
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parental smoking habits (not specified dosage or duration)
Study: 7631069
Drug: Fetal dopaminergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fetal dopaminergic tissue implants by the open microsurgical technique
Study: 7631069
Drug: Fetal mesencephalic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fetal mesencephalic cell suspension transplants (7 unilateral and 9 bilateral)
Study: 25730930
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (medicamental therapy only)
Study: 20005079
Drug: Antiepileptic drug
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drug treatment
Study: 2203556
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg, alternate-day intake)
Study: 360766
Drug: Thiethylperazine 6.5
Normalized name: thiethylperazine 6.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiethylperazine 6.5 mg, 2 capsules a day for 5 days
Study: 360766
Drug: Meclizine 25
Normalized name: meclizine 25 MG
DrugBank: Meclizine (DB00737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meclizine 25 mg, 2 capsules a day for 5 days
Study: 23510444
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment (mean weight-adjusted total daily dose at end of phase II was 27.8 mg/kg/day, average lithium concentration of 1.0 mEq/L)
Study: 23510444
Drug: Adjunctive psychotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive psychotropic medications (up to two could be prescribed)
Study: 19576495
Drug: Monocular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monocular therapy with latanoprost
Study: 17241503
Drug: Lidocaine 0.5
Normalized name: LIDOCAINE 0.5% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 0.5 mg kg(‐1) (Group 3)
Study: 17241503
Drug: Dexmedetomidine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.25 microg kg(‐1) plus lidocaine 0.25 mg kg(‐1) (Group 4)
Study: 17241503
Drug: Dexmedetomidine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.25 microg kg(‐1) plus lidocaine 0.5 mg kg(‐1) (Group 5)
Study: 17241503
Drug: Incidence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incidence of withdrawal movement after rocuronium injection
Study: 7973771
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with cisplatin 50 mg/m2 days 1 and 8 every 4 weeks during the 16 weeks, and vinorelbine 30 mg/m2 weekly for 16 weeks.
Study: 7973771
Drug: Vinorelbine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 30 mg/m2 weekly for 5 weeks with a 50% dose reduction planned for week 2 only, in combination with cisplatin 100 mg/m2 during weeks 1 and 5, and accelerated fractionation thoracic irradiation during weeks 7 to 10.
Study: 5090667
Drug: Water miscible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water miscible preparation of α‐tocopheryl acetate, daily dose of 1 mg/kg body weight
Study: 5090667
Drug: Fat soluble
Normalized name: Fat soluble vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat soluble preparation of α‐tocopheryl acetate
Study: 31725319
Drug: High sodium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sodium intake (15 g/day for 7 days)
Study: 11179544
Drug: Second-generation dihydropyridine
Normalized name: 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation dihydropyridine calcium channel blockers
Study: 9258853
Drug: 8% carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% carbohydrate solution
Study: 8070007
Drug: Epirubicin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (75 mg/m2) administered intravenously
Study: 8070007
Drug: Epirubicin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (75 mg/m2) administered via hepatic artery
Study: 8070007
Drug: Lignocaine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine (1 mg/kg) administered intravenously
Study: 8070007
Drug: Epirubicin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (75 mg/m2)
Study: 8070007
Drug: Intravenous epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous epirubicin
Study: 31738621
Drug: FDA approved
Normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDA approved medications for IBS-D
Study: 31738621
Drug: Emerging therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emerging therapies for IBS-D
Study: 28365177
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (cholecalciferol; 100,000 IU, once-monthly)
Study: 23982218
Drug: Vanadyl sulfate
Normalized name: Vanadyl Sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vanadyl sulfate 25 mg V daily
Study: 23982218
Drug: Vanadyl sulfate
Normalized name: Vanadyl Sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vanadyl sulfate 50 mg V daily
Study: 23982218
Drug: Vanadyl sulfate
Normalized name: Vanadyl Sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vanadyl sulfate 100 mg V daily
Study: 12940805
Drug: Naratriptan (2.5-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naratriptan (2.5-mg tablet)
Study: 12940805
Drug: Naproxen (500-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500-mg capsule)
Study: 10861337
Drug: Choline supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline supplementation (8.425 g choline citrate)
Study: 8210986
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A retention enemas (250 mg daily)
Study: 3538802
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy (beta-blockade and calcium antagonists)
Study: 29520772
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily kiwifruit consumption for 5 months
Study: 24150198
Drug: Fixed high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed high (FH; 0.067 mg/kg/day)
Study: 24150198
Drug: Individually adjusted
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually adjusted (IA; 0.035 mg/kg/day) after 3 months
Study: 24150198
Drug: Individually adjusted
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually adjusted (IA; 0.035 mg/kg/day) continued low dose
Study: 18794652
Drug: Quetiapine (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (titrated up to 400 mg/d, then 400-600 mg/d depending on clinical response)
Study: 16644334
Drug: Azimilide 125
Normalized name: Azimilide
DrugBank: Azimilide (DB04957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azimilide 125 mg twice daily for 3 days then once daily
Study: 8844441
Drug: Controlled-release oxycodone
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Controlled-release oxycodone 10 mg
Study: 10492054
Drug: Controlled-release oxycodone
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Controlled-release oxycodone 20 mg
Study: 8844441
Drug: Controlled-release oxycodone
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Controlled-release oxycodone 30 mg
Study: 8844441
Drug: Immediate-release oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release oxycodone 15 mg
Study: 8844441
Drug: Immediate-release oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release oxycodone 10 mg plus acetaminophen 650 mg (APAP)
Study: 26347514
Drug: SQT+NAC (N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQT+NAC (N-acetylcysteine 400 mg bid for the first 5 days)
Study: 26347514
Drug: SQT-only (rabeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQT-only (rabeprazole 20 mg and amoxicillin 1 g for the first 5 days, followed by rabeprazole 20 mg, clarithromycin 500 mg and metronidazole 500 mg for the remaining 5 days)
Study: 25494054
Drug: 0.3 g·kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g·kg‐1 BICA
Study: 25494054
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g of sodium chloride (placebo)
Study: 8641322
Drug: SCH 42354
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 42354 400 mg BID
Study: 8641322
Drug: SCH 42354
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 42354 300 mg BID
Study: 8641322
Drug: SCH 42354
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 42354 (entire dose range)
Study: 2138704
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg ramipril p.o.
Study: 6158390
Drug: Aspirin therapy
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin therapy for 1 week
Study: 6158390
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy for 48 h
Study: 31158253
Drug: Biological Hall
Normalized name: Halls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological Hall technique (HT)
Study: 25981651
Drug: Hange-shashin-to; administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hange-shashin-to; administered to 12 patients
Study: 24058300
Drug: Oral tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral tenofovir and emtricitabine/tenofovir with adherence counseling
Study: 21939520
Drug: Budesonide (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (800 μg daily for 3 months)
Study: 18997196
Drug: rosuvastatin, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin, 20 mg daily
Study: 16243115
Drug: Resveratrol combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol combined with l-NOARG (10(‐4) M)
Study: 7595908
Drug: Low-dose verapamil
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose verapamil
Study: 69938
Drug: Topical thrombin
Normalized name: thrombin Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical thrombin applied locally to the wound
Study: 23437966
Drug: Mirtazapine (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (after long-term paroxetine treatment)
Study: 23437966
Drug: Paroxetine (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (long-term treatment, 18.7 weeks on average)
Study: 21752726
Drug: Placebo intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intervention (identically-looking placebo drug)
Study: 21752726
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug (homeopathic remedy)
Study: 12798881
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.625 mg of esterified estrogens and 1.25 mg of methyltestosterone
Study: 12798881
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg of esterified estrogens
Study: 1475511
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not treated with fibrinolytic agents)
Study: 6383615
Drug: Captopril (CPT)
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril (CPT) 25 mg + Hydrochlorothiazide (HCT) 25 mg BID
Study: 6383615
Drug: Oxprenolol (OXP)
Normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxprenolol (OXP) 80 mg + Chlorthalidone (CHLT) 10 mg BID
Study: 29906455
Drug: FITOPROT A
Approvals — FDA: no, EMA: no, PMDA: no
Description: FITOPROT A - mucoadhesive formulation containing 10 mg/mL of curcuminoids extract plus 20% v/v of Bidens pilosa L. extract
Study: 29906455
Drug: FITOPROT B
Approvals — FDA: no, EMA: no, PMDA: no
Description: FITOPROT B - mucoadhesive formulation containing 20 mg/mL of curcuminoids extract plus 40% v/v of Bidens pilosa L. extract
Study: 27491226
Drug: Berberine Capsule
Normalized name: Xymogen Berberine Capsules
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberine Capsule (BC) 300 mg, thrice per day for 3 months
Study: 27491226
Drug: Placebo 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 300 mg, thrice per day for 3 months
Study: 22333403
Drug: Everolimus introduction
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus introduction with calcineurin inhibitor (CNI) reduction
Study: 30231851
Drug: Standard CNI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard CNI therapy
Study: 18574391
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus aspirin (75 mg/day with a 300 mg loading dose for 14 days)
Study: 7498103
Drug: Dietary supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplementation with a physiological dose of water‐soluble vitamins (fortified fruit juice containing 50 g carbohydrate and 50% of the daily dietary recommendations of water‐soluble vitamins)
Study: 7048948
Drug: Oltipraz 25
Normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oltipraz 25 mg/kg body weight
Study: 7048948
Drug: Oltipraz 35
Normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oltipraz 35 mg/kg body weight
Study: 29425836
Drug: Smartphone-based daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone-based daily feedback and communication platform
Study: 24763866
Drug: Clinical Significant
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical Significant Medication Errors (CSME)
Study: 12086380
Drug: Terminalia arjuna
Normalized name: terminalia arjuna
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terminalia arjuna (500 mg 8 hourly)